897-15-4 Usage
Chemical Properties
White or faintly yellow, crystalline powder.
Uses
Different sources of media describe the Uses of 897-15-4 differently. You can refer to the following data:
1. Dothiepin Hydrochloride is a tricyclic antidepressant.
2. Monoamine reuptake inhibitor; tricyclic antidepressant
Drug interactions
Potentially hazardous interactions with other drugsAlcohol: increased sedative effect.Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.Anticoagulants: may alter anticoagulant effect of
coumarins.Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, risperidone, sulpiride and
zuclopenthixol - avoid; increased antimuscarinic
effects with clozapine and phenothiazines;
concentration increased by antipsychoticsAntivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.Dapoxetine: possible increased risk of serotonergic
effects - avoidDopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Metabolism
Dosulepin hydrochloride is readily absorbed from the
gastrointestinal tract, and extensively demethylated by
first-pass metabolism in the liver to its primary active
metabolite, desmethyldothiepin (also termed northiaden).
Paths of metabolism also include S-oxidation.
Dosulepin is excreted in the urine, mainly in the form
of its metabolites; small amounts are also excreted in
the faeces. Elimination half-lives of about 14-24 and
23-46 hours have been reported for dosulepin and its
metabolites, respectively.
Dose in renal impairment GFR (mL/min)
20-50 Dose as in normal renal function.
10-20 Start with small dose and titrate
according to response.
<10 Start with small dose and titrate
according to response.
Dose in patients undergoing renal
replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Unknown dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in
GFR=10-20 mL/min.
Important drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with
Check Digit Verification of cas no
The CAS Registry Mumber 897-15-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,9 and 7 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 897-15:
(5*8)+(4*9)+(3*7)+(2*1)+(1*5)=104
104 % 10 = 4
So 897-15-4 is a valid CAS Registry Number.
InChI:InChI=1/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H
897-15-4Relevant articles and documents
DOTHIEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
-
Page/Page column 20-21, (2010/11/29)
The invention relates to dothiepin, metabolites of dothiepin, isomers of the same, and pharmaceutically-acceptable salts and prodrugs of the same; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.
